Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25...

Descripción completa

Detalles Bibliográficos
Autores: Rondy, Marc, Kissling, Esther, Emborg, Hanne-Dorthe, Gherasim, Alin Manuel, Pebody, Richard, Trebbien, Ramona, Pozo Sanchez, Francisco, Larrauri, Amparo, McMenamin, Jim, Valenciano, Marta, I-MOVE/I-MOVE+ group, Delgado-Sanz, Concepcion, Oliva Dominguez, Jesus Angel, Casas Flecha, Inmaculada
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/8992
Acceso en línea:http://hdl.handle.net/20.500.12105/8992
Access Level:acceso abierto
Palabra clave:Adolescent
Adult
Aged
Child
Child, Preschool
Europe
European Union
Female
Humans
Infant
Infant, Newborn
Influenza A Virus, H1N1 Subtype
Influenza A Virus, H3N2 Subtype
Influenza B virus
Influenza Vaccines
Influenza, Human
Male
Middle Aged
Pandemics
Treatment Outcome
Vaccination
Seasons
Descripción
Sumario:Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

Similares en LA Referencia